Lorusso 2016.

Study characteristics
Methods	Multicentre, retrospective review of consecutive women who underwent NACT‐IDS in 5 Italian centres
Participants	N = 193 participants with advanced‐stage ovarian cancer
Residual disease details	3 NACT cycles: 77 (44%) 4 NACT cycles: 74 (38%) 5 NACT cycles or more: 43 (22%) Text suggests residual disease was treated as NMRD vs any macroscopic RD (> 0 cm)
Outcomes	5‐year overall survival (OS) was 46% and 31% for women having 3 and 4+ cycles of NACT 10‐year OS was 26% and 18% for women having 3 and 4+ cycles of NACT "A trend towards worse OS was observed for women with residual disease at IDS": HR 1.29 (95% CI 0.98 to 1.70), P = 0.06 Unknown number of covariates in model except for ECOG performance status. Residual disease variable presumed to be RD > 0 cm vs NMRD.
Risk of bias (QUIPS)	1. Study participation (a‐f): high risk Abstract only therefore insufficient information on study participation 2. Study attrition (a‐e): unclear risk Unclear if patients with incomplete follow‐up were excluded before arriving at the stated sample size. Insufficient information to permit judgement. 3. Prognostic factor measurement (a‐f): low risk Valid and reliable measurement of RD Outcome level assessment: Outcome: overall survival 4. Outcome measurement (a‐c): low risk Definition of OS not provided but it usually has a standard definition. 5. Adjustment for other prognostic factors (a‐g): high risk Unclear on which variables were adjusted for but we know there is at least ECOG and number of NACT cycles 6. Statistical analysis and reporting (a‐d): high risk No conceptual framework; unclear on reasons why the particular specific set of variables were selected for multivariate model Outcome: progression‐free survival Not reported
Notes	Abstract only